Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Summary

The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.

Timeline

Start

2023-02-13

Primary completion

2026-12-31

Completion

2027-09-30

Drugs

Indications